1 January 2024 false No description of principal activity Taxfiler 2024.6 14529078business:PrivateLimitedCompanyLtd2024-01-012025-03-31 145290782023-12-31 145290782024-01-012025-03-31 14529078business:AuditExemptWithAccountantsReport2024-01-012025-03-31 14529078business:FilletedAccounts2024-01-012025-03-31 145290782025-03-31 14529078business:Director12024-01-012025-03-31 14529078business:RegisteredOffice2024-01-012025-03-31 145290782023-12-31 14529078core:WithinOneYear2025-03-31 14529078core:WithinOneYear2023-12-31 14529078core:AfterOneYear2025-03-31 14529078core:AfterOneYear2023-12-31 14529078core:ShareCapitalcore:PreviouslyStatedAmount2025-03-31 14529078core:ShareCapitalcore:PreviouslyStatedAmount2023-12-31 14529078core:RetainedEarningsAccumulatedLossescore:PreviouslyStatedAmount2025-03-31 14529078core:RetainedEarningsAccumulatedLossescore:PreviouslyStatedAmount2023-12-31 14529078core:PreviouslyStatedAmount2025-03-31 14529078core:PreviouslyStatedAmount2023-12-31 14529078business:SmallEntities2024-01-012025-03-31 14529078countries:EnglandWales2024-01-012025-03-31 14529078core:FurnitureFittings2024-01-012025-03-31 14529078core:FurnitureFittings2023-12-31 14529078core:FurnitureFittings2025-03-31 145290782022-12-082023-12-31 iso4217:GBP xbrli:pure
Company Registration No. 14529078 (England and Wales)
PRIME RESPONSE PHARMACY LTD Unaudited accounts for the period from 1 January 2024 to 31 March 2025
PRIME RESPONSE PHARMACY LTD Unaudited accounts Contents
Page
Company information
3
Accountants' report
4
Statement of financial position
5
Notes to the accounts
6
- 2 -
PRIME RESPONSE PHARMACY LTD Company Information for the period from 1 January 2024 to 31 March 2025
Director
IKHEKO IYARE EVBUOMWAN
Company Number
14529078 (England and Wales)
Registered Office
2A CONNAUGHT AVENUE LONDON E4 7AA UNITED KINGDOM
Accountants
TL LEADS ACCOUNTANCY LTD 124 CITY ROAD LONDON EC1V 2NX
- 3 -
Chartered Certified Accountants' report to the board of directors on the preparation of the unaudited statutory accounts of PRIME RESPONSE PHARMACY LTD for the period from 1 January 2024 to 31 March 2025
In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the accounts of PRIME RESPONSE PHARMACY LTD for the period from 1 January 2024 to 31 March 2025 as set out on pages 5 - 7 from the Company's accounting records and from information and explanations you have given us.
As a practising member firm of the Association of Chartered Certified Accountants, we are subject to its ethical and other professional requirements which are detailed at https://www.accaglobal.com/uk/en/about-us/regulation/rulebook.html
Our work has been undertaken in accordance with the requirements of the Association of Chartered Certified Accountants as detailed at http://www.accaglobal.com/content/dam/ACCA_Global/Technical/fact/technical-factsheet-163.pdf.
TL LEADS ACCOUNTANCY LTD Chartered Certified Accountants 124 CITY ROAD LONDON EC1V 2NX 1 December 2025
- 4 -
PRIME RESPONSE PHARMACY LTD Statement of financial position as at 31 March 2025
2025 
2023 
Notes
£ 
£ 
Fixed assets
Tangible assets
4
185,917 
1,804 
Current assets
Inventories
27,664 
- 
Debtors
5
4,000 
- 
Cash at bank and in hand
(9,531)
224 
22,133 
224 
Creditors: amounts falling due within one year
6
(3,500)
(750)
Net current assets/(liabilities)
18,633 
(526)
Total assets less current liabilities
204,550 
1,278 
Creditors: amounts falling due after more than one year
7
(357,389)
(20,000)
Net liabilities
(152,839)
(18,722)
Capital and reserves
Called up share capital
50 
50 
Profit and loss account
(152,889)
(18,772)
Shareholders' funds
(152,839)
(18,722)
For the period ending 31 March 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The director acknowledges her responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A - Small Entities. The profit and loss account has not been delivered to the Registrar of Companies.
The financial statements were approved by the Board and authorised for issue on 1 December 2025 and were signed on its behalf by
IKHEKO IYARE EVBUOMWAN Director Company Registration No. 14529078
- 5 -
PRIME RESPONSE PHARMACY LTD Notes to the Accounts for the period from 1 January 2024 to 31 March 2025
1
Statutory information
PRIME RESPONSE PHARMACY LTD is a private company, limited by shares, registered in England and Wales, registration number 14529078. The registered office is 2A CONNAUGHT AVENUE, LONDON, E4 7AA, UNITED KINGDOM.
2
Compliance with accounting standards
The accounts have been prepared in accordance with the provisions of FRS 102 Section 1A Small Entities. There were no material departures from that standard.
3
Accounting policies
The principal accounting policies adopted in the preparation of the financial statements are set out below and have remained unchanged from the previous period, and also have been consistently applied within the same accounts.
Basis of preparation
The accounts have been prepared under the historical cost convention as modified by the revaluation of certain fixed assets.
Presentation currency
The accounts are presented in £ sterling.
Tangible fixed assets and depreciation
Tangible assets are included at cost less depreciation and impairment. Depreciation has been provided at the following rates in order to write off the assets over their estimated useful lives:
Fixtures & fittings
18%
4
Tangible fixed assets
Fixtures & fittings 
£ 
Cost or valuation
At cost 
At 1 January 2024
2,200 
Additions
225,011 
At 31 March 2025
227,211 
Depreciation
At 1 January 2024
396 
Charge for the period
40,898 
At 31 March 2025
41,294 
Net book value
At 31 March 2025
185,917 
At 31 December 2023
1,804 
5
Debtors
2025 
2023 
£ 
£ 
Amounts falling due within one year
Trade debtors
4,000 
- 
- 6 -
PRIME RESPONSE PHARMACY LTD Notes to the Accounts for the period from 1 January 2024 to 31 March 2025
6
Creditors: amounts falling due within one year
2025 
2023 
£ 
£ 
Other creditors
3,500 
750 
7
Creditors: amounts falling due after more than one year
2025 
2023 
£ 
£ 
Bank loans
148,127 
- 
Trade creditors
41,920 
- 
Other creditors
28,000 
- 
Loans from directors
139,342 
20,000 
357,389 
20,000 
8
Average number of employees
During the period the average number of employees was 5 (2023: 1).
- 7 -